[Treatment of prolactinoma].
Prolactinomas rank first in frequency among hormone-secreting pituitary adenomas, but their management remains controversial. The authors present a review of the literature concerning the various therapeutic methods used and their results. As regards microadenomas, opinions are divided since the results obtained with bromocriptine and with selective adenomectomy are about the same. As regards macroadenomas, surgery exposes to more frequent complications and above all to recurrences. The majority of authors is in favour of bromocriptine first followed, if necessary, by surgical excision. Pregnancy may accelerate the development of prolactinomas. This risk is minimal with microadenomas and more real with macroadenomas, requiring more radical treatment before pregnancy and close monitoring.
Service de Médecine Interne B, Hôpital du Cluzeau, CHRU, Limoges.
S
S
Nadalon
B
B
De Buhan
F
F
Archambeaud-Mouveroux
M P
MP
Fournier
M C
MC
Huc
B
B
Laubie
D001971:Bromocriptine / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D011247:Pregnancy; D011379:Prognosis; D015175:Prolactinoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D012008:Recurrence; D013997:Time Factors
D001971:Bromocriptine
Traitement des adénomes à prolactine.